CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $20M, lower than 95% of all stocks globally
- FinancialsLow earnings quality
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.45BUSDvs all stocks (USD)
Revenue (TTM)
20.00MUSDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
52-Week Change
3.37%vs all stocks
Market Capitalization
1.45BUSDvs all stocks (USD)
Enterprise Value
1.10BUSDvs all stocks (USD)
Forward P/E
-8.20xvs Biotechnology peers
Price to Sales (TTM)
72.35xvs Biotechnology peers
Price to Book (MRQ)
3.19xvs Biotechnology peers
Enterprise to Revenue
54.82xvs Biotechnology peers
Enterprise to EBITDA
-7.63xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
-728.06%vs Biotechnology peers
Return on Assets (TTM)
-21.79%vs Biotechnology peers
Return on Equity (TTM)
-37.35%vs Biotechnology peers
Revenue (TTM)
20.00MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.3770USDUpdated Sep 28, 2026Quarterly Revenue Growth
-100.00%vs Biotechnology peers
Gross Profit (TTM)
20.00MUSDvs all stocks (USD)
EBITDA (TTM)
-143.71MUSDvs all stocks (USD)
Net Income (TTM)
-133.59MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-106.54MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-63.63MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 28, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-142.90MUSDvs all stocks (USD)
Pre-tax Income
-131.12MUSDFY2025 · Dec 31, 2025Income Tax Expense
0.00USDFY2025 · Dec 31, 2025Net Income
-131.12MUSDFY2025 · Dec 31, 2025EBIT
-142.90MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-140.50MUSDFY2025 · Dec 31, 2025Research & Development
108.45MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
34.45MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
11.78MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-131.12MUSDFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00USDFY2025 · Dec 31, 2025Operating Cash Flow
-112.48MUSDFY2025 · Dec 31, 2025Free Cash Flow
-113.28MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
190.34MUSDFY2025 · Dec 31, 2025Income Tax Paid
0.00USDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-131.12MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
2.40MUSDFY2025 · Dec 31, 2025Stock-based Compensation
16.40MUSDFY2025 · Dec 31, 2025Other Non-cash Items
2.65MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-27.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-2.79MUSDFY2025 · Dec 31, 2025Capital Expenditures
-794.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-187.67MUSDFY2025 · Dec 31, 2025Sale of Investments
17.50MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-170.96MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
0.00USDFY2025 · Dec 31, 2025Other Financing Charges
-500.00KUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
269.77MUSDFY2025 · Dec 31, 2025Shares Outstanding
55.50MSharesUpdated Sep 28, 2026Float Shares
36.76MSharesUpdated Sep 28, 2026Shares Short
5.68MSharesUpdated Sep 28, 2026Short Ratio
12.34daysvs all stocks
Short % of Shares Outstanding
11.51%vs all stocks
% Held by Insiders
1.55%vs all stocks
% Held by Institutions
106.79%vs all stocks
Total Cash (MRQ)
411.09MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
7.40USDUpdated Sep 28, 2026Total Debt (MRQ)
60.42MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.1333xvs Biotechnology peers
Current Ratio (MRQ)
18.31xvs Biotechnology peers
Book Value per Share (MRQ)
8.16USDUpdated Sep 28, 2026Total Assets
397.13MUSDvs all stocks (USD)
Total Current Assets
349.72MUSDFY2025 · Dec 31, 2025Total Liabilities
42.16MUSDFY2025 · Dec 31, 2025Total Non-current Assets
47.41MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
19.61MUSDFY2025 · Dec 31, 2025Total Current Liabilities
22.56MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
189.25MUSDFY2025 · Dec 31, 2025Other Short-term Investments
152.67MUSDFY2025 · Dec 31, 2025Accounts Payable
1.79MUSDFY2025 · Dec 31, 2025Short-term Debt
4.79MUSDFY2025 · Dec 31, 2025Long-term Debt
18.51MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
1.09MUSDFY2025 · Dec 31, 2025Common Stock (Book)
49.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-489.55MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
354.97MUSDvs all stocks (USD)
52-Week Low
21.95USDUpdated Sep 28, 202652-Week High
53.65USDUpdated Sep 28, 202652-Week Change
3.37%vs all stocks
50-Day MA
27.16USDUpdated Sep 28, 2026200-Day MA
33.30USDUpdated Sep 28, 2026Avg 10-Day Volume
1.08MSharesUpdated Sep 28, 2026Avg 30-Day Volume
654.55KSharesUpdated Sep 28, 2026Diluted EPS (TTM)
-2.44USDUpdated Sep 28, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.68
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $20M, lower than 95% of all stocks globallySignificant
Revenue (USD): 20,000,000Global P5: 33,357,653.812
Market cap is $1.45B, above the global median of $1.18BNotable
Market cap (USD): 1,447,055,770Global Median: 1,180,223,658.953
Companies that share the same coordination system — how they create, deliver, or capture value.
Omeros Corporation
Tier 1ProductionApproval-Gated PipelineRuleRisk
HBM Holdings Limited
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
KalVista Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Tianjin Chase Sun Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Mayinglong Pharmaceutical Group Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Ningbo Menovo Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Ultragenyx Pharmaceutical Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Inhibrx Biosciences, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Guangdong Taienkang Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Classys Inc.
Tier 1ProductionApproval-Gated PipelineRule